ABT icon

Abbott
ABT

Overview Fund Activity
134.17 USD
+1.41
1.06%
At close Updated Sep 17, 4:00 PM EDT
Pre-market
After hours
134.17
0.00
0%
1 day
1.06%
5 days
3.45%
1 month
2.99%
3 months
1.43%
6 months
5.12%
Year to date
18.27%
1 year
13.58%
5 years
25.79%
10 years
203.28%
 

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

Healthcare Medical Devices
0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 10 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

45% more first-time investments, than exits

New positions opened: 177 | Existing positions closed: 122

25% more call options, than puts

Call options by funds: $1.37B | Put options by funds: $1.1B

1.43% more ownership

Funds ownership: 77.69% [Q1] → 79.11% (+1.43%) [Q2]

7% more repeat investments, than reductions

Existing positions increased: 1,295 | Existing positions reduced: 1,209

4% more capital invested

Capital invested by funds: $179B [Q1] → $186B (+$7.82B) [Q2]

0% less funds holding

Funds holding: 3,126 [Q1] → 3,124 (-2) [Q2]

15% less funds holding in top 10

Funds holding in top 10: 115 [Q1] → 98 (-17) [Q2]

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$135
1% upside
Avg. target
$144
7% upside
High target
$155
16% upside

10 analyst ratings

8  positive
80%
2  neutral
20%
0  negative
0%
Citigroup
Joanne Wuensch
$155
Buy
Maintained
18 Jul 2025
Wells Fargo
Lawrence Biegelsen
$142
Overweight
Maintained
18 Jul 2025
Raymond James
Jayson Bedford
$141
Outperform
Maintained
18 Jul 2025
Mizuho
Anthony Petrone
$135
Neutral
Maintained
18 Jul 2025
Jefferies
Matthew Taylor
$145
Buy
Upgraded
18 Jul 2025
See Analyst Rankings

Financial journalist opinion

Based on 21 articles about ABT published over the past 30 days

Neutral
Zacks Investment Research
yesterday
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
Positive
Zacks Investment Research
yesterday
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Neutral
The Motley Fool
4 days ago
3 No-Brainer Dividend Stocks to Buy in September
Some decisions are tough to make. Others are so easy that they don't require much thought and are practically no-brainers.
3 No-Brainer Dividend Stocks to Buy in September
Positive
Zacks Investment Research
7 days ago
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
Positive
The Street
11 days ago
Inside Abbott's big bet on the future of healthcare
Abbott CEO highlights the company's devices that could make healthcare faster and easier.
Inside Abbott's big bet on the future of healthcare
Positive
The Motley Fool
13 days ago
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
The list of trillion-dollar stocks is small and doesn't feature a single medical company. That might change in the next decade, as several leading healthcare stocks have market caps that are inching closer to that milestone.
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
Negative
The Street
14 days ago
Abbott to take $200 million tariff hit: What it means for patients
Abbott's CEO explains what tariffs mean for the company and its patients. Transcript: CAROLINE WOODS: So while you're working on all of that, you're also having to plan for and account for tariffs that have been looming.
Abbott to take $200 million tariff hit: What it means for patients
Positive
Zacks Investment Research
15 days ago
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Positive
Zacks Investment Research
16 days ago
ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.
ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
Positive
Zacks Investment Research
19 days ago
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
Investors are showing growing interest in the rapidly expanding structural heart device market, which is expected to witness a compound annual growth rate (CAGR) of 13.5% between 2025 and 2033, according to Grand View Research. Abbott Laboratories ABT and Edwards Lifesciences EW are two key players with significant presence in this sector.
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
See News Rankings
Charts implemented using Lightweight Charts™